DR info

臨床試験数 : 8 / 薬物数 : 8 - (DrugBank : 3) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 6

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Lonafarnib
   Boston Children's Hospital
      2009   Phase 2   NCT00879034   United States;
   Eiger BioPharmaceuticals
      2020   -   NCT03895528   -
   Monica E. Kleinman
      2007   Phase 2   NCT00425607   United States;
Lonafarnib, Zoledronic Acid, and Pravastatin
   Boston Children's Hospital
      2009   Phase 2   NCT00916747   United States;
Pravastatin
   Boston Children's Hospital
      2009   Phase 2   NCT00879034   United States;
Progerinin
   PRG Science & Technology Co., Ltd.
      2020   Phase 1   NCT04512963   United States;
Umbilical Cord Blood Unit
   Bundang CHA Hospital
      2019   Phase 1/Phase 2   NCT03871972   Korea, Republic of;
Zoledronic acid, pravastatin
   Assistance Publique Hopitaux De Marseille
      2008   Phase 2   NCT00731016   France;